Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6544936 | 0.72 | — | — | |
| SCHEMBL12463565 | 0.71 | — | — | |
| SCHEMBL7793728 | 0.69 | L3MBTL1 (0.36) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL21456613 | 0.65 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL15177067 | 0.64 | — | — | |
| SCHEMBL4304979 | 0.64 | — | — | |
| SCHEMBL6548346 | 0.64 | CYP3A4 (0.46) | ALDH1A1LMNAKDM4EMAPTKMT2A | |
| SCHEMBL3879787 | 0.64 | TSHR (0.42) | ALDH1A1LMNAKDM4EMAPTGLO1 | |
| SCHEMBL1418707 | 0.62 | ALDH1A1 (0.56) | ALDH1A1LMNAKDM4EMAPTGLO1 | |
| SCHEMBL5514458 | 0.62 | SMN1; SMN2 (0.57) | ALDH1A1KDM4EKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643326-B1 | Process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-ol | MYLAN LAB LTD (IN) | 2016-09-14 | — | — | EP | disclosed |
| US-9216990-B2 | Crystalline Darunavir | MYLAN LABS LIMITED (IN) | 2015-12-22 | — | — | US | disclosed |
| US-20140350270-A1 | Crystalline Darunavir | Mylan Laboratores LTD (IN) | 2014-11-27 | — | — | US | disclosed |
| US-8841467-B2 | Process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro [2, 3-b] furan-3-ol | MYLAN LABORATORIES LIMITED (IN) | 2014-09-23 | — | — | US | disclosed |
| EP-2643326-A1 | PROCESS FOR THE PREPARATION OF (3R, 3AS, 6AR)-HEXAHYDROFURO [2, 3- B]FURAN-3-OL | Mylan Laboratories, Limited (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20130244297-A1 | PROCESS FOR THE PREPARATION OF (3R, 3AS, 6AR)-HEXAHYDROFURO [2, 3- B] FURAN-3-OL | Mylan Laboratories Ltd. (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2013114382-A1 | CRYSTALLINE DARUNAVIR | MYLAN LABORATORIES LTD (IN) | 2013-08-08 | — | — | WO | disclosed |
| WO-2012070057-A1 | PROCESS FOR THE PREPARATION OF (3R, 3AS, 6AR)-HEXAHYDROFURO [2, 3- B] FURAN-3-OL | MATRIX LABORATORIES LTD (IN) | 2012-05-31 | — | — | WO | disclosed |
| US-20100113589-A1 | Deuterated darunavir | CONCERT PHARMACCUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113589-A1 | Deuterated darunavir | CONCERT PHARMACCUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090131363-A1 | Deuterated darunavir | CONCERT PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| WO-2009055006-A1 | DEUTERATED DARUNAVIR | CONCERT PHARMACEUTICALS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-1638960-A4 | PREPARATION OF CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1532127-B1 | PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO(2,3-b) FURAN-3-OL | SMITHKLINE BEECHAM CORP (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20060148865-A1 | Preparation of chemical compounds | MARTIN MICHAEL T | 2006-07-06 | — | — | US | disclosed |
| EP-1638960-A2 | PREPARATION OF CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050261507-A1 | Preparation of stereoisomers of (3alpha/beta, 6alpha/beta)hexahydrofuro[2,3-b]furan-3-ol | SMITHKLINE BEECHAM CORPORATION | 2005-11-24 | — | — | US | disclosed |
| EP-1532127-A1 | PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO(2,3-b) FURAN-3-OL | SmithKline Beecham Corporation (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2005000249-A2 | PREPARATION OF CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004002975-A1 | PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO[2,3-b]FURAN-3-OL | SMITHKLINE BEECHAM CORPORATION (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244297-A1 | PROCESS FOR THE PREPARATION OF (3R, 3AS, 6AR)-HEXAHYDROFURO [2, 3- B] FURAN-3-OL | HPD, HAAO, DHRS9 | ALDH1A1 1730/4885LMNA 4354/4885KDM4E 1559/4885 |
| US-20090131363-A1 | Deuterated darunavir | SAMHD1, DUT, DNPEP | ALDH1A1 1062/4885LMNA 4346/4885KDM4E 1441/4885 |
| US-20050261507-A1 | Preparation of stereoisomers of (3alpha/beta, 6alpha/beta)hexahydrofuro[2,3-b]furan-3-ol | BACE1, DPP3, BACE2 | ALDH1A1 445/4885LMNA 2445/4885KDM4E 3514/4885 |
| US-20140350270-A1 | Crystalline Darunavir | SAMHD1, DARS1, DUT | ALDH1A1 3331/4885LMNA 2528/4885KDM4E 2796/4885 |
| US-20100113589-A1 | Deuterated darunavir | SAMHD1, DUT, DNPEP | ALDH1A1 1062/4885LMNA 4346/4885KDM4E 1441/4885 |
| US-20060148865-A1 | Preparation of chemical compounds | HTR3C, QDPR, CYP2C9 | ALDH1A1 235/4885LMNA 3345/4885KDM4E 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.